Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. (OTCQX: BLGO) regularly issues news and updates about its cleantech, environmental, energy, and life sciences activities. As a developer of sustainable technologies and a full-service environmental engineering company, its announcements often focus on progress in PFAS water treatment, advanced wastewater solutions, odor and VOC control, air quality, energy storage, and medical infection control and wound care.
Recent news has highlighted BioLargo’s Aqueous Electrostatic Concentrator (AEC) platform, including reported breakthroughs that significantly reduced the system’s energy use in large-scale PFAS treatment and its deployment at a municipal drinking water facility in Lake Stockholm, New Jersey. Coverage also includes recognition of BioLargo Equipment Solutions & Technologies, Inc. in industry media for PFAS treatment advances and updates on commercial demonstration projects.
Investors and observers can also find announcements about BioLargo’s Cellinity battery technology for grid-scale energy storage, its role in broader infrastructure and clean energy discussions, and participation in conferences and investor events such as LD Micro and NobleCon. These items provide context on how the company positions its technologies within evolving infrastructure, data center, and energy investment cycles.
On the life sciences side, news items cover Clyra Medical Technologies’ progress in infection control and advanced wound care, including the ViaCLYR wound irrigation solution and its exclusive distribution alliance with Advanced Solution, LLC. Regulatory, legal, and corporate developments—such as SEC-reported events, financial updates, and intellectual property enforcement actions related to odor control technologies—are also common topics. This news page allows readers to follow BioLargo’s ongoing technical milestones, commercialization steps, and corporate disclosures in one place.
BioLargo (OTCQX:BLGO) installed its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system at the Lake Stockholm municipal water facility in New Jersey on January 27, 2026. The AEC is designed to remove both long- and short-chain PFAS and operate with minimal contaminated residual waste, addressing Lake Stockholm's lack of an onsite waste outlet. The installation will undergo commissioning and 12 months of special NJDEP monitoring with EPA coordination to generate data and confirm readiness for sustained municipal service. BioLargo says the system is expected to treat PFAS to levels that exceed EPA and New Jersey drinking water standards and could support further municipal opportunities.
BioLargo (OTCQX:BLGO) will present at Sidoti's Micro-Cap Virtual Conference on Thursday, January 22, 2026 at 1:00 PM Eastern. BioLargo President & CEO Dennis P. Calvert will host the presentation and discuss ongoing business developments.
The event is a virtual Sidoti forum that connects small- and micro-cap issuers with investors. The live webinar requires registration at the Sidoti webinar link and provides a venue for investor Q&A and company updates.
BioLargo (OTCQX: BLGO) closed 2025 highlighting disciplined development and early-stage deployments across environmental, energy, and medical platforms. Key 2025 advances include an Aqueous Electrostatic Concentrator (AEC) install for PFAS removal at a Lake Stockholm, New Jersey municipal plant, progress toward public-private Cellinity battery factory collaborations, and Clyra Medical's first production run for ViaClyr with distributor Advanced Solution under contract.
Management expects potential meaningful commercial revenue from Clyra in 2026, continued validation from clinical KOLs, and alignment of BioLargo technologies with a large infrastructure investment cycle, while noting timing and execution remain uncertain.
BioLargo (OTCQX:BLGO) announced its subsidiary BioLargo Equipment Solutions & Technologies was featured in Chemical Engineering for its Aqueous Electrostatic Concentrator (AEC) PFAS treatment, described as producing "nearly zero waste" while removing long-, short-, and ultra-short-chain PFAS. The company also delivered an AEC system to the Lake Stockholm, New Jersey drinking water facility and is supporting provisioning, integration, and commissioning with the general contractor.
Company statements note the delivery is the final stage before the AEC goes live for the Lake Stockholm community and reference New Jersey settlements exceeding $2.5 billion that support PFAS cleanup efforts.
BioLargo (OTCQX: BLGO) will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon 21) on December 3, 2025 at 10:30 AM Eastern in Boca Raton, FL.
President & CEO Dennis P. Calvert will address prior-year financial results and ongoing business developments. The conference features formal presentations, fireside chats, one-on-one meetings and networking with hundreds of public company executives and keynote speakers.
Investors can attend the in-person session at Presentation Room 4 or learn more about the conference at nobleconference.com and company technologies at biolargo.com.
Summary not available.
BioLargo (OTCQX:BLGO) will host an investor webcast and conference call on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET to review results for the quarter ended September 30, 2025, discuss recent milestones, and hold a Q&A session.
Live access: register at the webcast page at least 15 minutes early. Teleconference numbers and participant code are provided for domestic and international callers. A replay is available through February 14, 2027, and the webcast replay plus presentation materials will be posted on BioLargo's Investor Relations page at www.biolargo.com/investor-relations.
BioLargo (OTCQX:BLGO) subsidiary Clyra Medical Technologies signed an exclusive stocking distribution agreement with Advanced Solution to distribute ViaCLYR™ nationwide in the United States.
ViaCLYR™ uses Clyra's proprietary Clyrasept™ copper-iodine complex, described as antimicrobial and shown to have safety, efficacy, biocompatibility, and cost-effectiveness in FDA-cleared applications. The product is scheduled for market launch in early 2026. The alliance pairs Clyra's technology with Advanced Solution's national distribution network and clinical training capabilities to accelerate adoption across healthcare providers.
Summary not available.
BioLargo (OTCQX:BLGO) announced a breakthrough upgrade to its patented Aqueous Electrostatic Concentrator (AEC) that cuts energy use by more than 90% for large-scale PFAS treatment versus prior AEC generations. The company cites prior May 2025 data showing up to 80% total life-cycle cost savings versus carbon technologies and claims non-detect PFAS removal <1 ppt in drinking and brackish water.
Example: a 1,000 gpm municipal system could see monthly energy costs fall from ~$208,000 to ~$15,700 (>$2.3M annual savings at $0.15/kWh). An industrial test showed 88% energy reduction; waste is reported as 1/40,000th that of carbon systems. A first commercial installation in New Jersey is nearing operation.
FAQ
What is the current stock price of Biolargo (BLGO)?
What is the market cap of Biolargo (BLGO)?
